Skip to main content
Sign In

Clinical Research Studies Enrolling

The Barbara Davis Center for Diabetes, located at the University of Colorado Anschutz Medical Campus, is actively involved in clinical research. The research division has several on-going studies, as well as ones that are ope​n for enrollment. These studies are all dedicated to the screening and understanding of type 1 diabetes, the pursuit of preventing diabetes in high-risk patients as well as clinical intervention for those already diagnosed with type 1 diabetes.

The studies listed below are currently enrolling eligible participants. The BDC is a nationally recognized diabetes research center.​

Abatacept Prevention Study

To determine whether a drug called abatacept can delay or prevent disease progression in Stage 1 Type 1 Diabetes between the ages of 6 to 45.

Pathway to Prevention Study​

Detecting T1D at its earliest stage.


Natural History Study of the Development of Type 1 Diabetes - Monitoring

Identified as having positive diabetes autoantibodies through TrialNet Pathway to Prevention study screening.

A Twin Family Study of Islet Cell Autoimmunity

To determine the relative contribution of genetic and environmental factors to the early stages of and progression to type 1 diabetes and related autoimmune diseases.

Simponi to Arrest β-cell Loss in Type 1 Diabetes

To determine if Simponi (golimumab) can preserve β-cell function in children and young adults with newly diagnosed type 1 diabetes (T1D).

Anti-CD3 MAB (Teplizumab) for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

To see if 14 consecutive days of the study drug, Teplizumab, can delay or prevent Type 1 Diabetes in relatives at risk for developing the disease.

Long Term Investigative Follow-up in TrialNet (LIFT)

To help us learn more about factors involved in preservation of insulin production after being diagnosed with Type 1 Diabetes​.

A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal CD4+CD25+CD127lo/-FOXP3+ Regulatory T-cells [Tregs]) in Adolescents with Recent Onset Type 1 Diabetes Mellitus (T1DM)

A Phase 1b Study to Evaluate an Investigational Medication in Children, Adolescents, and Young Adults with Pre-Symptomatic Type 1 Diabetes​

To determine the safety and tolerability of an investigational medication in children, adolescents, and young adults with pre-symptomatic Stage 2 Type 1 Diabetes (T1D).

Hydroxychloroquine Prevention Study
To determine whether the drug hydroxychloroquine (HCQ) can prevent or delay disease progressin in participants age 3 or older who have two or more diabetes-related autoantibodies and normal glucose tolerance (Stage 1 Type 1 Diabetes (T1D))
MAS-1 Adjuvanted Antigen-Specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes​
To determine if insulin B-Chain adjuvant with MAS-1 is safe and will favor tolerogenic pathways to restore immunologic balance and reverse T1D autoimmunity.